Un nuevo coronavirus, una nueva enfermedad: COVID-19

  • Carlos Guillermo Quiroz Carrillo Universidad de San Martín de Porres, Facultad de Medicina Humana, Instituto de Investigación, Centro de Investigación de Infectología e Inmunología. Lima, Perú. http://orcid.org/0000-0002-4821-9496
  • Arturo Pareja Cruz Universidad de San Martín de Porres, Facultad de Medicina Humana, Instituto de Investigación, Centro de Investigación de Infectología e Inmunología. Lima, Perú. http://orcid.org/0000-0002-5988-5515
  • Edward Valencia Ayala Universidad de San Martín de Porres, Facultad de Medicina Humana, Instituto de Investigación, Centro de Investigación de Infectología e Inmunología. Lima, Perú. http://orcid.org/0000-0002-5318-5526
  • Yanina Pastora Enriquez Valencia Universidad de San Martín de Porres, Facultad de Medicina Humana, Instituto de Investigación, Centro de Investigación de Infectología e Inmunología. Lima, Perú. http://orcid.org/0000-0002-8501-0915
  • Joel De Leon Delgado Universidad de San Martín de Porres, Facultad de Medicina Humana, Instituto de Investigación, Centro de Investigación de Infectología e Inmunología. Lima, Perú. http://orcid.org/0000-0002-3664-8023
  • Priscilia Aguilar Ramirez Universidad de San Martín de Porres, Facultad de Medicina Humana, Instituto de Investigación, Centro de Investigación de Infectología e Inmunología. Lima, Perú.

Resumen

La nueva pandemia de COVID-19 causada por el virus SARS-CoV-2 desafía actualmente a la humanidad. Este virus originario de murciélagos ha sido transmitido a humanos, probablemente, a través del pangolín en el mercado marino de Wuhan (China) a fines del 2019. Se disemina por gotitas de saliva o a través de materiales contaminados, por lo que es sumamente importante aislar a las personas infectadas que pueden ser sintomáticas o asintomáticas. El cuadro clínico típico se caracteriza por fiebre, tos seca, dificultad respiratoria y malestar general. Este integrante de la familia de los coronavirus tiene mayor capacidad infectiva que sus predecesores, pero una menor mortalidad (2-3 %). Las pruebas de laboratorio para detectar la presencia del virus se basan en la reacción en cadena de la polimerasa con transcriptasa inversa (RT-PCR, por su sigla en inglés) o en inmunoensayos.

##plugins.generic.usageStats.downloads##

##plugins.generic.usageStats.noStats##

Citas

1. Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, et al. Coronavirus infections and immune responses. J Med Virol. 2020; 92(4): 424-32.
2. Gorbalenya AE, Baker SC, Baric RS, De Groot RJ, Drosten C, Gulyaeva AA, et al. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020; 5: 536-44.
3. Organization World Health. Coronavirus disease 2019 (COVID-19) Situation Report. Genova: WHO; 2020.
4. Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, et al. SARS-CoV-2: Infection in Children. N Engl J Med. 2020.
5. Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. The Lancet. 2020; 395(10226): 809-15.
6. Wang S, Guo L, Chen L, Liu W, Cao Y, Zhang J, et al. A case report of neonatal COVID-19 infection in China. Clin Infect Dis. 2020.
7. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The Lancet. 2020; 395(10224): 565-74.
8. Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. Nat Med. 2020.
9. Zhang W, Li X, Chen J, Shi J, Duan G, Chen X, et al. A furin cleavage site was discovered in the S protein of the 2019 novel coronavirus. Virology. 2020; 18: 2.
10. Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2. Science. 2020.
11. Jaimes JA, André NM, Millet JK, Whittaker GR. Structural modeling of 2019-novel coronavirus (nCoV) spike protein reveals a proteolytically-sensitive activation loop as a distinguishing feature compared to SARS-CoV and related SARS-like coronaviruses. bioRxiv. 2020.
12. Corman VM, Muth D, Niemeyer D, Drosten C. Chapter Eight - Hosts and Sources of Endemic Human Coronaviruses. In: Kielian M, Mettenleiter TC, Roossinck MJ, editors. Advances in Virus Research; 2018. p. 163-88.
13. Ge X-Y, Li J-L, Yang X-L, Chmura AA, Zhu G, Epstein JH, et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature. 2013; 503(7477): 535-8.
14. Zaki AM, Van Boheemen S, Bestebroer TM, Osterhaus ADME, Fouchier RAM. Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia. N Engl J Med. 2012; 367(19): 1814-20.
15. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798): 270-3.
16. Organization World Health. Novel Coronavirus - China Genova. WHO; 2020.
17. Organization World Health. Coronavirus disease 2019 (COVID-19) Situation Report. Genova: WHO; 2020.
18. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. N Engl J Med. 2020.
19. Chan JF-W, Yuan S, Kok K-H, To KK-W, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. The Lancet. 2020; 395(10223): 514-23.
20. Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, et al. Transmission of 2019-nCoV Infection from an asymptomatic contact in Germany. N Engl J Med. 2020; 382(10): 970-1.
21. Li R, Pei S, Chen B, Song Y, Zhang T, Yang W, et al. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2). Science. 2020.
22. Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med. 2020; 382(12): 1177-9.
23. Pan Y, Zhang D, Yang P, Poon LLM, Wang Q. Viral load of SARS-CoV-2 in clinical samples. Lancet Infect Dis. 2020; 20: 30113-4.
24. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First case of 2019 Novel Coronavirus in the United States. N Engl J Med. 2020; 382(10): 929-36.
25. Thevarajan I, Nguyen THO, Koutsakos M, Druce J, Caly L, Van de Sandt CE, et al. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nat Med. 2020.
26. Van Doremalen N, Bushmaker T, Morris D, Holbrook M, Gamble A, Williamson B, et al. Aerosol and surface stability of HCoV-19 (SARSCoV-2) compared to SARS-CoV-1. N Engl J Med. 2020.
27. Guan W-J, Ni Z-Y, Hu Y, Liang W-h, Ou C-q, He J-x, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020.
28. Du W, Yu J, Wang H, Zhang X, Zhang S, Li Q, et al. Clinical characteristics of COVID-19 in children compared with adults in Shandong, China. Res Square. 2020.
29. Centers for Disease Control and Prevention. Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) - United States, February 12-March 16, 2020. United States: CDC; 2020.
30. Yang R, Gui X, Xiong Y. Patients with respiratory symptoms are at greater risk of COVID-19 transmission. Lancet Respir Med. 2020.
31. Yang X, Yu Y, Xu J, Shu H, Xia Ja, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020.
32. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?. Lancet Respir Med. 2020.
33. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis. 2020.
34. Liu Y, Bi L, Chen Y, Wang Y, Fleming J, Yu Y, et al. Active or latent tuberculosis increases susceptibility to COVID-19 and disease severity. N Engl J Med. 2020.
35. Du W, Yu J, Wang H, Zhang X, Zhang S, Li Q, et al. Clinical characteristics of covid-19 in children compared with adults outside of hubei province in China. 2020.
36. Pan L, Mu M, Ren HG, Yang P, Sun Y, Wang R, et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. American J Gastroenterol. 2020.
37. Lippi G, Henry BM. Active smoking is not associated with severity of coronavirus disease 2019 (COVID-19). Eur J Case Rep Intern Med. 2020.
38. Huang P, Liu T, Huang L, Liu H, Lei M, Xu W, et al. Use of chest ct in combination with negative RT-PCR assay for the 2019 novel coronavirus but high clinical suspicion. Radiol. 2020; 295(1): 22-3.
39. Jin Y-H, Cai L, Cheng Z-S, Cheng H, Deng T, Fan Y-P, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res. 2020; 7(1): 4.
40. Kim JY, Ko JH, Kim Y, Kim YJ, Kim JM, Chung YS, et al. Viral load kinetics of SARS-CoV-2 infection in first two patients in Korea. J Korean Med Sci. 2020; 35(7): e86.
41. Newton AH, Cardani A, Braciale TJ. The host immune response in respiratory virus infection: balancing virus clearance and immunopathology. Springer Semin Inmunopathol. 2016; 38(4): 471-82.
42. Sheridan C. Fast, portable tests come online to curb coronavirus pandemic. Nat Biotechnol. 2020.
43. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020.
44. Zhou D, Dai S-M, Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrobial Chemo. 2020.
45. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30(3): 269-71.
46. Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. 2. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020: 105949.
47. Colson P, Rolain J-M, Lagier J-C, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents. 2020: 105932.
48. Rosa SGV, Santos WC. Clinical trials on drug repositioning for COVID-19 treatment. Pan Am J Public Health. 2020.
49. Jingyi X, Eunice YCS, Huizhi G, Jessica YW, Min WF, Sukhyun R, et al. Nonpharmaceutical measures for pandemic influenza in nonhealthcare settings-Personal protective and environmental measures. Emerg Infect Dis. 2020; 26(5).
Publicado
2020-04-04
Cómo citar
QUIROZ CARRILLO, Carlos Guillermo et al. Un nuevo coronavirus, una nueva enfermedad: COVID-19. Horizonte Médico (Lima), [S.l.], v. 20, n. 2, p. e1208, abr. 2020. ISSN 2227-3530. Disponible en: <http://www.horizontemedico.usmp.edu.pe/index.php/horizontemed/article/view/1208>. Fecha de acceso: 09 ago. 2020 doi: https://doi.org/10.24265/horizmed.2020.v20n2.11.
Sección
ARTÍCULOS DE REVISIÓN